home / stock / pavmz / pavmz news

PAVMZ News and Press, PAVmed Inc. Series Z Warrant From 11/11/22

Stock Information
Company Name: PAVmed Inc. Series Z Warrant
Stock Symbol: PAVMZ
Market: NASDAQ
Website: pavmed.com
Menu
PAVMZ PAVMZ Quote PAVMZ Short PAVMZ News PAVMZ Articles PAVMZ Message Board
Get PAVMZ Alerts

News, Short Squeeze, Breakout and More Instantly...
PAVMZ - PAVmed to Participate in BTIG Digital Health Forum

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D. , PAVmed&#...
PAVMZ - Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced tha...

PAVMZ - Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the...

PAVMZ - PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022

Company conference call and webcast at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a diversified commercial-stage medical device company today announced that the Company will host a business update conference call and webcast on Tuesday, November 15, 2022, at...
PAVMZ - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced t...

PAVMZ - PAVmed to Participate in the Lake Street 6th Annual Best Ideas Growth Conference and the A.G.P. Virtual MedTech Conference

PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical device company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D., the Company&#x...

PAVMZ - PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed press release ( NASDAQ: PAVM ): Q2 Non-GAAP EPS of -$0.17 beats by $0.03 . PAVmed had cash and cash equivalents of $65.2 million as of June 30, 2022, compared with $77.3 million as of December 31, 2021. Shares +3.03% . For further details see: ...
PAVMZ - PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results

Lucid’s EsoGuard test volume grows 60% and LucidDx Labs fully operational Veris Health Cancer Care Platform to commercially launch this year Conference call to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Com...

PAVMZ - Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

Patients in Orange County, Dallas-Fort Worth, Palm Beach County, and Columbus, Ohio now have access to a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer Lucid Diagnostics Inc. (Nasdaq: LUCD) (...

PAVMZ - Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics' EsoGuard® and EsoCheck® Technologies

Updates best practice advice to support non-endoscopic esophageal precancer screening and significantly expands target population to include, for the first time, at-risk patients without chronic heartburn symptoms Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lu...
Previous 10 Next 10